ライフサイエンスコーパス: preclinical model

1 I-induced advanced AAA in a well-established preclinical model.

2 introduction of exogenous collagen VII in a preclinical model.

3 indings in a well-characterized large animal preclinical model.

4 tively curb cancer stem cell properties in a preclinical model.

5 -gated sodium channels is neuroprotective in preclinical models.

6 ade of CCR2 restores anti-tumour immunity in preclinical models.

7 ope and showed strong anti-tumor activity in preclinical models.

8 oxidative stress and kill ABC-DLBCL cells in preclinical models.

9 lucose analogs ameliorates aggressive PKD in preclinical models.

10 w excellent efficacy and minimal bleeding in preclinical models.

11 es (FGFR/PTENi) show only modest activity in preclinical models.

12 ncer and promotes colonic tumor formation in preclinical models.

13 ported as osteoinductive in multiple in vivo preclinical models.

14 chemopotentiation in p53-deficient tumors in preclinical models.

15 nase with single-agent antitumor activity in preclinical models.

16 differentiation and reducing tumor growth in preclinical models.

17 notypes characterized by fearful behavior in preclinical models.

18 ropathology, and behavioral function in aged preclinical models.

19 trated potential to enhance drug delivery in preclinical models.

20 livery of viruses for cancer gene therapy in preclinical models.

21 various coadministered substances in several preclinical models.

22 h better than either single agent in several preclinical models.

23 acy of chemotherapy and improved survival in preclinical models.

24 therapy with rituximab enhanced activity in preclinical models.

25 ave been shown to be safe and immunogenic in preclinical models.

26 es treatment from several weeks to 7 days in preclinical models.

27 both in vitro assays and in vivo orthotopic preclinical models.

28 peutic activities in vitro and in vivo using preclinical models.

29 splatin, reduces tumor growth effectively in preclinical models.

30 rotumorigenic activity of WAT progenitors in preclinical models.

31 activity of chemotherapy and radiotherapy in preclinical models.

32 ppressing leptomeningeal metastasis in these preclinical models.

33 iomarker than GlcCer for neuronopathic GD in preclinical models.

34 onogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastru

35 genetic and pharmacological evidence that in preclinical models ACC is required to maintain the de no

36 The homogenous nature of the preclinical models allows for reproducibility, which is

37 to inhibit UVB-induced immunosuppression in preclinical model and, thus, has potential for use as a

38 astasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment

39 uctive translational research dialog between preclinical models and clinical studies of these disorde

40 tion, with several agents being evaluated in preclinical models and clinical trials.

41 While this approach has been promising in preclinical models and early clinical trials, widespread

42 Integration of Treg biology gleaned from preclinical models and experiences in human organ transp

43 sed OV (Pexa-Vec) has shown good efficacy in preclinical models and in clinical trials.

44 namics readouts to monitor their efficacy in preclinical models and in HD patients.

45 are effective in inhibiting angiogenesis in preclinical models and in treating several angioprolifer

46 une responses ensued and was observed across preclinical models and patients undergoing high-dose int

47 ned the functional role of Mer in the CNS in preclinical models and performed correlative studies in

48 f action of OX40- and CD27-targeting mAbs in preclinical models and provide an overview of current cl

49 modifiers alter disease progression in both preclinical models and subjects with Duchenne muscular d

50 ogic and physiologic differences between the preclinical models and the human condition, study design

51 c targets in cardiovascular tissues, in both preclinical models and translational studies.

52 of an extensive repertoire of transgenes to preclinical models and, more recently, clinical trials i

53 in glioblastoma multiforme (GBM) cell lines, preclinical models, and clinical samples, we demonstrate

54 tem cell biology, including culture systems, preclinical models, and functional assessment, may impro

55 Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines

56 However, in vitro preclinical models are essential tools for both the stud

57 nstrated superior reconstitution capacity in preclinical models, are the most abundant circulating T-

58 Niraparib was characterized in a number of preclinical models before moving to phase I clinical tri

59 ned the effects of PTEN knockdown in several preclinical models (both in cell lines intrinsically sen

60 on NAFLD, insulin resistance, and obesity in preclinical models but is too toxic for clinical use.

61 r (NMDAR) antagonists are neuroprotective in preclinical models, but have been clinically unsuccessfu

62 1 acquisition in humans can be elicited in a preclinical model by a poxvirus prime-gp120 boost strate

63 Because preclinical models can inform translational studies of n

64 Herein, preclinical models, case reports, and clinical trials of

65 tform aiming for a comprehensive overview of preclinical models covering genetically engineered organ

66 Studies in humans and preclinical models demonstrate lasting gene expression c

67 Preclinical models demonstrating therapeutic effects of

68 In a preclinical model developed in our laboratory, rats exhi

69 Although use of in vivo preclinical models employing primary leukemic cells is f

70 23414 demonstrates efficacy against EAC in a preclinical model, establishing the rationale for clinic

71 This study introduces a highly tractable preclinical model for interrogating sex differences in U

72 eERT transgenic mice could serve as a useful preclinical model for investigating underlying mechanism

73 s the article by Wang et al that describes a preclinical model for targeting BRAF-mutant gliomas.

74 l tumors and therefore represent a promising preclinical model for the early assessment of therapy ef

75 To establish a preclinical model for therapeutic inhibition of putative

76 s a framework for the proper use of existing preclinical models for drug testing and discovery.

77 In preclinical models for Duchenne muscular dystrophy, dyst

78 s directions for the development of improved preclinical models for infection, as well as for the des

79 digm for designing more flexible and dynamic preclinical models for these as well as other acute leuk

80 as been successfully applied in a variety of preclinical models, generally focused on targeting the d

81 ted regarding enhanced erlotinib response in preclinical models harboring the patient tumor somatic v

82 Progress propelled by preclinical models has led to a deeper understanding on

83 Although preclinical models helped to define and predict certain

84 autoimmune diseases and numerous studies in preclinical models highlights the potential of regulator

85 In preclinical models, ibrutinib reduced severity of cGVHD.

86 evelop new psychiatric interventions through preclinical models if we take animal emotional feelings

87 We have previously demonstrated, with a preclinical model in rodents, that adolescent alcohol us

88 myeloid leukemia (AML) is the limitations of preclinical models in capturing inter- and intrapatient

89 e it restores CTCL apoptosis in vitro and in preclinical models in vivo and prevents spreading of the

90 Preclinical models in which human gut communities are re

91 In preclinical models in which sclerodermatous cGVHD develo

92 Using a preclinical model, in the current work, we identify a se

93 rimary leukemic cells is first choice, newer preclinical models including "organoids" and combination

94 loped a (99m)Tc-labeled CXCL8 preparation in preclinical models including colitis and clinical studie

95 Taken together, these data from multiple preclinical models, including a strong reliance on prima

96 Using multiple preclinical models, including NK coculture (autologous a

97 These preclinical models indicate a causal, microbiota-depende

98 Evidence from preclinical models indicates that xenon gas can prevent

99 Inhibition of PSMA in preclinical models inhibited PI3K signaling and promoted

100 The tooth root fenestration preclinical model is an ideal tool for hard tissue evalu

101 Moreover, type 1 diabetes reversal in preclinical models is accompanied by the selective expan

102 In addressing this issue, preclinical models may be limited by the inability to ac

103 rkers downstream of gemcitabine treatment in preclinical models may provide an insight into resistanc

104 he genomic and histologic diversity, correct preclinical models need to reproduce drug response obser

105 Despite several promising leads in preclinical models, no agent has yet been approved for c

106 When extrapolated to a preclinical model of a human GBM cell line, we find an i

107 ion and significantly improves survival in a preclinical model of advanced stage epithelial ovarian c

108 d by the lack of a physiologically relevant, preclinical model of allogeneic HSCT.

109 PET imaging and treatment of tumors in this preclinical model of AVPC.

110 derivatives to visualize B1R expression in a preclinical model of B1R-positive tumors.

111 In a preclinical model of breast cancer, beta3 was strongly e

112 dated our conclusions experimentally using a preclinical model of Burkitt's lymphoma.

113 in TgNotch3(R169C) mice, a well-established preclinical model of CADASIL.

114 osylation, would have improved outcomes in a preclinical model of cerebral malaria.

115 ted sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neu

116 ished disease, or viral exacerbation using a preclinical model of chronic asthma and in vitro human p

117 e encephalomyelitis (EAE), a widely accepted preclinical model of chronic MS.

118 Here, we demonstrate in a preclinical model of colitis-induced colorectal cancer t

119 Here, in a preclinical model of critical limb ischemia, we assessed

120 of Nrf2, has a strong protective effect in a preclinical model of cSCC.

121 y in the nonanesthetized mouse, an important preclinical model of disease and development.

122 te esophageal eosinophilic inflammation in a preclinical model of EoE.

123 val and activation) would be protective in a preclinical model of EoE.

124 In this preclinical model of FA, metformin outperformed the curr

125 gical inhibitors of MRTF/SRF signalling in a preclinical model of fibrosis.

126 and guide Abraxane delivery into tumors in a preclinical model of human A375 melanoma.

127 Findings were confirmed in a preclinical model of human chemotherapy-induced intestin

128 Using a preclinical model of IL-17-mediated dry eye disease, we

129 sociated with improved cardiac function in a preclinical model of ischemic cardiomyopathy.

130 We studied acute and chronic rejections in a preclinical model of ITX, which recapitulates clinical f

131 s in a translationally relevant large animal preclinical model of myocardial infarction (MI).

132 y inhibit IgM binding and reduce injury in a preclinical model of myocardial infarction.

133 iral vector carrying I-1c (BNP116.I-1c) in a preclinical model of nonischemic HF, and to assess thoro

134 We developed and validated a novel preclinical model of opioid self-administration by inhal

135 leukocytes would impact graft survival in a preclinical model of orthotopic left lung transplantatio

136 for investigation of mast cell biology and a preclinical model of passive cutaneous anaphylaxis and p

137 ds were advanced for further evaluation in a preclinical model of PCa.

138 of HGF in combination with gemcitabine in a preclinical model of PDAC reduces primary tumor volume a

139 tion, and promising therapeutic profile in a preclinical model of prostate cancer.

140 ion-induced rectal damage in humans and in a preclinical model of radiation proctitis in mice.

141 tal mucosal and submucosal microvessels in a preclinical model of radiation proctitis in Tie2-green f

142 cue of both rod and cone photoreceptors in a preclinical model of RP.

143 vestigate the pathological role of IFNs in a preclinical model of sclerodermatous graft-versus-host d

144 We describe a novel preclinical model of stress-induced relapse to cocaine u

145 Yet, an accurate preclinical model of these phenotypes that includes earl

146 Preclinical modeling of the fibrotic process remains cha

147 Because of technical obstacles, preclinical modeling of UTI in male mice has been limite

148 etalloproteinases), have proven effective in preclinical models of abdominal aortic aneurysm and show

149 -inflammatory properties and is effective in preclinical models of acute inflammation and autoimmunit

150 fficacy of a TcdA/B RBD-based DNA vaccine in preclinical models of acute toxin-associated and intraga

151 research because of the gap between current preclinical models of addiction and the clinical criteri

152 e last 50 years to the development of recent preclinical models of addiction that more closely mimic

153 l discovery of pharmacologic combinations in preclinical models of adjuvant treatment and therapeutic

154 f current standard-of-care chemotherapies in preclinical models of advanced pancreatic and ovarian ca

155 axel and androgen receptor (AR) targeting in preclinical models of advanced prostate cancer.

156 tic therapy approaches have been explored in preclinical models of AF, and offer potential as a treat

157 nergy with the BCL-2 inhibitor venetoclax in preclinical models of AML.

158 r of the para-caspase MALT1, is effective in preclinical models of another type of BCR pathway-depend

159 have been investigated for their efficacy in preclinical models of anxiety, cough, substance abuse, p

160 fects of cortistatin in two well-established preclinical models of atherosclerosis, and the molecular

161 of action of the BTK inhibitor ibrutinib in preclinical models of B-ALL.

162 Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma.

163 and selectivity in the prevention of GVHD in preclinical models of bone marrow transplantation.

164 robiological mechanisms of DMN processing in preclinical models of both normal and disease states.

165 vely correlates with that drug's efficacy in preclinical models of breast, liver and colon cancers.

166 ical development, has shown activity in both preclinical models of cancer as well as in patients with

167 In many cellular and preclinical models of cancer, eIF4F deregulation results

168 mit the cytotoxic effects of chemotherapy in preclinical models of cancer.

169 ely, increase drug uptake or decrease IFP in preclinical models of carcinoma.

170 y in vitro and in vivo, including in various preclinical models of CDI.

171 used to image cell survival and rejection in preclinical models of cell therapy.

172 Preclinical models of Chagas disease have demonstrated t

173 reported to demonstrate in vivo activity in preclinical models of cognition.

174 er disease states and are neuroprotective in preclinical models of critical illness.

175 ins have shown growth-inhibitory activity in preclinical models of CRPC.

176 Compound 19a was further studied in two preclinical models of disease, exhibiting good efficacy

177 e imaging of glycosylated tissues in vivo in preclinical models of disease.

178 regulation have yielded promising results in preclinical models of disease.

179 ations for optimal efficacy are derived from preclinical models of disseminated tuberculosis that rec

180 ciclib represses MCL-1 protein expression in preclinical models of DLBCL.

181 nib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without

182 the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for interrogation

183 tude and duration of the initial response in preclinical models of EML4-ALK lung adenocarcinoma.

184 tionale for future studies targeting Ncad in preclinical models of EOC metastasis.

185 targets periostin and evaluated the probe in preclinical models of esophageal squamous cell carcinoma

186 In preclinical models of experimental metastasis, ectopic e

187 In preclinical models of glioblastoma, antigen escape varia

188 Thus there is a need for preclinical models of HD recapitulating human HTT geneti

189 ty to cisplatin both in vitro and in vivo in preclinical models of HNSCC.

190 approach-avoidance conflict tests are common preclinical models of human anxiety disorder.

191 inhibited disease progression in aggressive preclinical models of human cancers and induced cell kil

192 eneration of more sophisticated and accurate preclinical models of human cancers.

193 R-7-5p (miR-7), in both in vitro and in vivo preclinical models of human HCC and identified miR-7 as

194 atforms for periadventitial drug delivery in preclinical models of IH as well as insights about barri

195 dly more effective than imatinib in multiple preclinical models of imatinib-sensitive and imatinib-re

196 of the NLRP3 inflammasome and its outputs in preclinical models of inflammation and disease.

197 en developed, and two have shown efficacy in preclinical models of inflammatory disease.

198 his channel in mediating hypersensitivity in preclinical models of inflammatory or neuropathic pain.

199 molecular immune response in two widely used preclinical models of inflammatory pain: (i) intraplanta

200 Studies in preclinical models of influenza virus infections have sh

201 iopsies from patients with active IBD and in preclinical models of intestinal inflammation.

202 l-signaling activity, have shown benefits in preclinical models of ischemic stroke, brain trauma, mul

203 Research Domain Criteria-driven preclinical models of isolated behaviors and domains inv

204 type II JAK2 inhibitor that is effective in preclinical models of JAK2-dependent myeloproliferative

205 strategy towards the development of scalable preclinical models of liver stage malaria infection for

206 with P7C3 compounds has been demonstrated in preclinical models of neurodegeneration by virtue of pro

207 enefit of young blood has not been tested in preclinical models of neurodegeneration or AD.

208 se 2 (NMNAT2) is neuroprotective in numerous preclinical models of neurodegeneration.

209 ating drugs show various salutary effects in preclinical models of neurodegenerative disease.

210 e subtle changes in microglial activation in preclinical models of neuroinflammation.

211 carboxypeptidase II (GCPII) is effective in preclinical models of neurological disorders associated

212 provides potent neuroprotection in numerous preclinical models of neurological disorders.

213 (Nav1.7) plays an important role in multiple preclinical models of neuropathic pain and in inherited

214 ngi but does not have a well-defined role in preclinical models of non-pathogen-mediated inflammation

215 how these neural systems are dysregulated in preclinical models of obesity.

216 antitumor potency of these agents in several preclinical models of pancreatic cancer.

217 ing further development and investigation in preclinical models of pancreatic tumorigenesis.

218 ptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease.

219 y of ALN-GO1 to reduce oxalate production in preclinical models of PH1 across multiple species and pr

220 stasis-targeting peptidomimetic (BMTP-11) in preclinical models of primary intratibial osteosarcomas,

221 ection of compound 25a for its assessment in preclinical models of psychosis.

222 Based on synergy in preclinical models of PTCL, we initiated a phase 1 study

223 olite, nitrite, have therapeutic activity in preclinical models of pulmonary hypertension.

224 ptotic function of Bcl-2 is highly active in preclinical models of refractory acute myeloid leukemia

225 Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of po

226 Preclinical models of stroke have shown that intravenous

227 agents that are showing newfound promise in preclinical models of stroke therapy.

228 chiatric disorders and have shown promise in preclinical models of substance abuse.

229 o, allowing creation of genetically accurate preclinical models of these disorders.

230 tized toward 1, and 1 is under evaluation in preclinical models of these tumor types.

231 omic rearrangements and to generate accurate preclinical models of this lethal human cancer.

232 Of relevance to this aim, preclinical models of threat memory reduction are consid

233 acid, NO2-OA), were investigated in multiple preclinical models of TNBC.

234 errin and (18)F-FDG imaging were compared in preclinical models of TNBC.

235 Tr1) cell-mediated induction of tolerance in preclinical models of transplantation is remarkably effe

236 s potential therapeutic approach in relevant preclinical models of viral infections.

237 ntibody titers correlated with protection in preclinical models of ZEBOV infection, Tfh were predicte

238 Preclinical models often fail to capture the diverse het

239 An illustration of the impact of the age of preclinical models on pharmacokinetic properties is also

240 fractionation studies have been performed in preclinical models, optimal drug exposures, and PK/PD pa

241 g lung adenocarcinoma clinical specimens and preclinical models, our computational analyses revealed

242 he development of increasingly sophisticated preclinical models over the recent years has provided th

243 In preclinical models, p38 inhibitors reduce lung injury fo

244 Different methods are currently used in preclinical models: partial hepatectomy, portal ligature

245 ogical tools to study anti-ZIKV responses in preclinical models, particularly T cell responses, remai

246 ave not replicated the promising findings in preclinical models, perhaps because these compounds tend

247 pevonedistat has significant activity in MCL preclinical models, possibly related to effects on NF-ka

248 We demonstrate that our preclinical model recapitulates the cardio-respiratory d

249 Using humanized mice, a preclinical model relevant to human physiology, we show

250 Broad efficacy in a set of preclinical models relevant to AD suggests that inhibiti

251 , none of them recapitulate AT/RT, for which preclinical models remain lacking.

252 Preclinical models reveal that stress-induced amygdala a

253 Preclinical models revealed that the immune system can m

254 In preclinical models, STN DBS provides neuroprotection for

255 Furthermore, studies in preclinical models suggest that decreasing IL-6 activity

256 Preclinical models suggest that these rapid antidepressa

257 ectively, these findings are consistent with preclinical models suggesting that the dentate gyrus and

258 ted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportuni

259 metastatic but not tumorigenic potential in preclinical models, supporting a novel mechanism of regu

260 This study therefore established a powerful preclinical model system that permits the comprehensive

261 mphocytes, demonstrating the ability of this preclinical model system to identify molecular targets t

262 Despite assertions that some preclinical model systems are superior to others, no sin

263 CIPN investigations in preclinical model systems have focused on either behavio

264 d in cancer immunology is the development of preclinical model systems that are immunocompetent for t

265 Preclinical model systems that capture the genetic and f

266 the translation of pharmacokinetic data from preclinical model systems to humans.

267 luded the following: the need for innovative preclinical model systems to study metastatic disease; i

268 This review will focus on the preclinical model systems used to evaluate TIM and explo

269 tion of such emerging targets, sophisticated preclinical model systems, and the molecular classificat

270 exhibited potent antitumor activity in four preclinical model systems, including MMTV-huHER2 and huC

271 ourage investigations of R-baclofen in other preclinical model systems.

272 large bone defects in the mandible require a preclinical model that accurately recapitulates the rege

273 ent-derived xenografts (PDXs) are a reliable preclinical model that closely recapitulates the main ch

274 We sought to develop a preclinical model that fully recapitulates the symptoms

275 We describe a preclinical model that investigates progression of early

276 A preclinical model that maintains physiologic mechanical

277 therapeutic antibodies by using appropriate preclinical models that accurately reflect the unique af

278 comes in non-small cell lung cancer (NSCLC), preclinical models that can better predict individual pa

279 -modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique fe

280 administration for human substance abusers, preclinical models that incorporate inhaled exposure to

281 of death in the developed world, yet facile preclinical models that mimic the natural stages of CRC

282 In nonviral preclinical models, the angiogenic cytokine VEGF-A has b

283 Based on the phenotypes of our preclinical models, the FLCN H255Y mutant protein has lo

284 nce to BET inhibitors has been documented in preclinical models, the molecular mechanisms underlying

285 In preclinical models, the use of a purified, naive T cell

286 In preclinical models these mutations cause accumulation of

287 ice as a highly reproducible immunocompetent preclinical model to evaluate HIV-1 acquisition across t

288 We utilized an in vivo preclinical model to perform a PK-PD analysis of systemi

289 However, an optimal preclinical model to study retinoblastoma invasiveness a

290 There has been a recent expansion of preclinical models to predict the efficacy of regimens t

291 experimental conditions can serve as precise preclinical models to study mechanisms involved in breas

292 f the biology of osteosarcoma and the use of preclinical models to test novel agents will be critical

293 istance, people have successfully tested, in preclinical models, treatments targeting specific resist

294 In preclinical models tumour-derived VEGF limits immune cel

295 ective radiosensitizing agents in a range of preclinical models using broad field sources of various

296 mmed death-ligand 1 (PD-L1) expression, in a preclinical model, using a small high-affinity engineere

297 Based on preclinical models we proposed that noradrenergic denerv

298 Factor (TF) can contribute to thrombosis in preclinical models, we investigated whether plasma micro

299 fragments can increase arthritis severity in preclinical models, we then explored the effect of LBH d

300 erapeutics required translationally relevant preclinical models with well-characterized cancer genome